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INDUCES HOMOTYPIC CELL-CELL INTERACTIONS1
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In the present study a unique antibody (NKI-L16) 
reacting with the a-chain of the human leukocyte 
function-associated Ag-1 (LFA-1) is described» which 
stimulates homotypic cell-cell interactions in a man­
ner very similar to 12-0-tetradecanoyl-phorbol-13- 
acetate (TPA), in contrast to other anti-LFA -1 mAb 
which inhibit cell aggregation. The induction of ag­
gregate formation of EBV-transformed B cells (JY) and 
CTL clones by TPA or NKI-L 16 is not accompanied by 
an increase in the expression of LFA-1. Nevertheless, 
this cluster formation is LFA-1 dependent, inasmuch 
as anti-LFA-1 antibodies, other than NKI-L16, com­
pletely abrogate aggregation. Simultaneous addition 
of NKI-L16 and TPA did not result in a further increase 
of the speed of cluster formation, suggesting that a 
similar pathway is activated. Immunoprécipitation and 
enzyme digestion studies revealed that NKI-L16 rec­
ognizes a unique epitope on the a-chain of LFA-1, 
most likely situated close to the transmembrane seg­
ment of the molecule.
It is hypothesized that NKI-L 16 or TPA can cause 
the LFA-1 molecule to convert from an inactive to an 
active configuration, thereby permitting binding of LFA- 
1 to its natural ligand.
LFA-13 belongs to a family of adhesion molecules con­
sisting of LFA-1, CR3 (C3biR), and pl50.95. All three Ag 
are bimolecular glycoprotein complexes with an a f /3-sto- 
chiometry. They share a common ft subunit with a Mr of 
95 kDa but differ in their a subunits with Mr of 170, 165, 
and 150 kDa, respectively (1, 2).
LFA-1 was first identified by mAb that inhibit target cell 
lysis by cytotoxic T cell clones, both in mouse (3) and man 
(4, 5) by preventing conjugate formation (6, 7). Since then 
it has become clear that LFA-1 acts as a general cellular 
adhesion molecule mediating a variety of heterotypic and 
homotypic cell-cell interactions (2, 8—11).
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Both B and T lymphocytes can be induced to form ag­
gregates in vitro after stimulation with Ag, lectins, or phor- 
bol esters (TPA) (12, 13). These cell-cell interactions can be 
blocked by anti-LFA-1 mAb, indicating an important role 
for this molecule in intercellular adhesion processes (11, 
12).
In addition, recently three independent reports have been 
published which indicate that some anti-LFA-1 mAb are 
able to induce proliferation and cell aggregation in murine 
lymphocytes, which underlines the importance of LFA-1. 
The precise role of LFA-1 In this process is not clear, in­
asmuch as the proliferation occurred only after concomi­
tant addition of Ag (14), Con A supernatant (15), or anti­
bodies which cross-link the 5-chains of surface IgG molecules 
(16). However, the ability to use stimulatory and inhibitory 
mAb in immunologic processes may be very helpful in de­
lineating the working mechanism of LFA-1.
We now present the characteristics of a mAb directed 
against the human LFA-1 a-chain, which, in contrast to 
other anti-LFA-1 antibodies, stimulates rather than inhib­
its homotypic cell aggregate formation, but does not affect 
cell proliferation (G. D. Keizer, unpublished results). The 
results obtained with this antibody are very similar to those 
obtained after treatment of ceils with TPA. To the best of 
our knowledge, this is the first report of an antibody di­
rected against hum an LFA-1 which stimulates cell-cell con­
tact,
MATERIALS AND METHODS
A ntibod ies . The mAb SPV LI, SPV L7, and  SPV Ll I (further nam ed 
LI, L7, and  H I ,  respectively), and  CLB 54 were raised as described 
previously (2, 17). The mAb SPV-L10, NKÏ-L15, an d  NKI-L16 (further 
nam ed L10, LI 5, a n d  L16) were obtained  by im m uniz ing  BALB/e mice 
w ith  a CTL clone, JY cells, an d  monocytes, respectively. Hybridoma 
su p e rn a ta n ts  were screened for inh ib ition  of T cell-mediated 'killing or 
for inh ib ition  or s tim u la tion  of the  form ation of homotypic aggregates 
between JY cells. The mAb MHM 23 and  MHM 24 were a gift of Dr. A. 
McMichael (Nuffield D epartm ent, J o h n  RadclifTe Hospital, UK) (18). 
T he purified mAb 60.3 was kindly provided by Dr. M. Harlan (Depart­
m en ts  of Medicine, Pathology, and  Pediatrics, University of W ashing­
ton, Seattle) (19, 20). Two antibodies Klos and  Rupi-1 were used as 
controls. Klos recognizes an  idiotypic de te rm inan t on Ig. Ruipi-l rec­
ognizes an  Ag with a  Mv of 35 kDa on h u m a n  monocytes. Bolh a n t i ­
bodies are  nonreactive with the cells used, as  detected by im m unopré­
cipitation. All an tibodies were purified on a Baker-Bond mAb HPLC 
colum n (J. T. Baker, Philipsburg , NJ).
Cells, T he h u m a n  cytotoxic T cell clone JS -136  was used  in this 
study. T h is  clone is directed ag a in s t HLA-DR (21) an d  was cultured in 
serum -free m edium  (linolea) as described previously (22). Activated 
PBL were ob ta ined  by cu ltu ring  PBL, isolated by density  g rad ien t cen ­
trifugation  over Ficoll-Hypaque, in the presence ofPHA (0.1 /¿g/ml) for
4 clays. T he  h u m a n  EBV-transformed B cell line JY was cultured in 
linolea supp lem ented  w ith  2% h u m a n  AB serum .
Labeling o f  mAb, mAb were directly labeled with FITC by using  the 
following procedure. HPLC-purified mAb were dialyzed against 0.1 M
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Na2C03 (pH 8.5) for 2 h. Subsequently , 37.5 /¿g FITC (Sigma Isomer 
1. No. 7250) in 0.5 M Na2HCOLt (pH 9.6) were added to each mg of 
protein, followed by a 2-h incubation  al room tem perature. mAb-FITC 
conjugates were separa ted  from free FITC by m eans of a Bio-Gel P-2 
column (Bio-Rad, R ichm ond, CA).
Immunofluorescence.  Cells were incubated  for 30 m in  at 0°C in PBS 
containing 1% BSA (Sigma, St. Louis, MO), 0.01% sodium  azide, and 
appropriate d ilu tions of the different mAb followed by incubation  with 
FITC-labeled goat F(ab)2 an ti-m ouse  IgG antibody (Nordic, Tilburg, The 
Netherlands) for 30 m in  a t  0°C. T he relative fluorescence in tensity  was 
measured by FACS IV analysis, an d  was calculated as:
mAb
Fluorescence in tensity  of unlabeled cells.
Epitope determ ina tion .  1. T rypsin  digestion: PHA-activated PBL (5 
x 107) were w ashed twice an d  resuspended  in PBS at a concentration  
of 2 x 106 cells/ml. Sam ples of 250 /A of th is  suspension  (or equivalent 
amounts) were p re incubated  in 15-ml Falcon tubes a t 37°C for 5 min 
followed by the addition  of a sim ilar volume of PBS con ta in ing  trypsin 
(17.5 U/ml, Boehringer, M annheim , FRG) and  DNase-1 [stra in  Cowan- 
1, Sigma). The reaction was stopped  a t various time po in ts  by the 
addition of 14 ml ice-cold DMEM supplem ented  w ith  10% BSA and  
trypsin inh ib ito r (5 mg/ml, Boehringer M annheim). Subsequently  the 
cells were w ashed twice in the sam e m edium  and kept on ice until use 
in the im m unofluorescence assay. T he viability of the cells was >85% 
as determined by trypan blue exclusion.
2. Cross-blocking experim ents: To determ ine w hether the various 
mAb were directed aga ins t shared  or u n iq u e  epitopes, two different 
methods were applied. In m ethod  A, cells were incubated  w ith  appro­
priate dilutions of a  single mAb (mAb 1 o r  mAb 2) or w ith a  m ixture 
of two mAb (mAb 1 and mAb 2). Subsequently , cells were incubated  
with a FITC-labeled goat an ti-m ouse  IgG antibody after w hich  the RI 
was determined. mAb were judged  to sh a re  com m on epitopes, i.e., to 
cross-block each other, w hen the RI of the cells treated w ith  the m ixture 
of mAb did no t exceed the h ig h es t RI value of the cells treated  with a 
single mAb (either mAb 1 or mAb 2). Furtherm ore, mAb were defined 
to recognize u n iq u e  d e te rm in an ts  if  the  add ition  su m  of the RI values 
of cells treated with mAb 1 or w ith  mAb 2 w as equal ( ± 20%) to the  RI 
value of the cells treated  w ith  the  m ix tu re  of bo th  mAb 1 and 2. In 
method B, the mAb LI, L7, L l l ,  L I 6, an d  CLB 54 were directly labeled 
with FITC as described above. Cells were incubated  w ith  unlabeled mAb 
1 for 30 m in  at 4°C, followed by the addition  of FITC-labeled mAb 2, 
After 30 min, cells were w ashed  once w ith  PBS and  analyzed by FACS 
IV m easurem ents of the RI value. E ach  m easu rem en t was accom panied 
by a control sam ple to w h ich  only the  FITC-labeled mAb were added. 
Usage of m ethod A or B led to identical results .
Radiolabeling a n d  im m unoprécip ita tion .  Cell surface radioiodi- 
nation with Na 125I (Amersham, UK) w as catalyzed by 1,3,4,6-tetra- 
chloro-3o’,6o' diphenylglycoluril (lodogen, Pierce Chemical Co., Rock­
ford, IL) as described previously (23). For im m unoprécip ita tion  (24), 
radiolabeled cells were Iysed w ith  1% Nonidet P-40 in 0.01 M trietha- 
nolamine-HCl (pH 7.8), 0 .15 M NaCl, 1 mM PNSF, 0 .02  mg/ml ovo­
mucoid trypsin inh ib ito r (Sigma, TEA/NaCl buffer). Nuclear debris was 
removed from the lysates by cen trifugation  a t 13,000 x g for 15 min 
at 4°C. Material insoluble in  the lysis buffer was removed by centrif­
ugation a t  100,000 x g for 30 m in  in an  air-driven centrifuge (Beckman 
Instruments» Palo Alto, CA], Lysates were precleared fu rther by su c ­
cessive incubations w ith  formalin-fixed Staphylococcus aureus  (strain  
Cowan I) and m ouse IgG coupled to p ro te in  A Sepharose. Prccleared 
lysates were incubated  for 3 to 4  h  w ith  a specific mAb coupled to 
protein A Sepharose. T he im m unoprecip ita tes  were removed from the 
lysates by centrifugation a t 13,000 x p. Precipitates were resuspended  
in 0.2 ml TEA/NaCl buffer w ith  0.5% sodium  deoxycholate and  cen­
trifuged for 15 sec a t  13,000 x g.  Subsequently  im m unoprecip ita tes  
were washed extensively in  0.01 M TEA/HC1 (pH 7.8), 0.2% Nonidet P- 
40.
Electrophoresis a n d  au torad iography . SDS-PAGE was carried ou t 
on vertical slab gels (6 to 8% ) according to a  modification of the Laemmli 
procedure (25), as  described previously (2). Kodak XAR-film w as used 
in combination w ith  in tensifier screens (Cronex L ightning Plus, D u­
pont Chemical Co., Newton, CT) for au torad iography of 125I-labeled 
materials.
Peptide m apping .  To perform one-dim ensional peptide m apping, 
specific b an d s  were cu t ou t of the  gel th a t  h ad  previously been fixed, 
dried, and  au toradiographed . The gel slices were soaked in a Tris-HCl 
buffer, con ta in ing  0.5% SDS, for 15 m in, an d  were transferred  to a  
second gel (stacking gel 5%; ru n n in g  gel 15 to 17%). The gel slices were 
overlayered with 10 /xl 20% glycerol. S ubsequen tly  a second layer (10 
fi\) was adm inistered  con ta in ing  10% glycerol and V8 pro tease  (0.1 mg/ 
ml). Subsequently the gel was ru n  (100 V) un til the dye front of the 
sample buffer (of m.w. m arkers) reached the border between s tack ing
and  ru n n in g  gel. After an  incubation period of 30 m in  (25°C) running 
of the gel was continued  followed by fixation and autoradiography.
Q ualitative aggregation a ssa y . Homotypic aggregation of cells was 
m easured in a qualitative m anner by a modification of the method 
described by Rothlein an d  Springer (12). Cells were washed twice in 
linolea contain ing  1 % pooled AB serum  resuspended and seeded in 96- 
well m icrotiter plates (No. 3596, Costar, Cambridge). Each well con­
tained 1 x 105 cells, mAb (0.1 to 10 /xg/ml), and/or TPA (1 to 10 ng/ 
ml). Cells were incubated  for various periods of time (see Resuits) at 
37°C, after w hich aggregate formation was determined by at least two 
investigators by light microscopy. Scores ranged from 0 to 5-1- where 
0 indicated that essentially no cells were aggregated In clusters: 1 + 
indicated th a t <10%  of the cells were found in loose clusters: 2+ in­
dicated th a t <50% of the cells formed loose clusters: 3 + indicated that 
<80% of the cells were found in loose clusters; 4 + indicated that >80% 
of the cells were found in small compact aggregates: 5 + indicates that 
>90% of the cells formed large compact clusters. It was our experience 
th a t the differences in the results obtained by two independent ob­
servers was negligible.
Q uan tita ttue  aggregation assay.  Cells were seeded in flat bottom 
m icrotiter plates as  described above. The num ber of nonaggregating 
cells was counted by the use of a calibrated mask consisting of squares 
(0.46 mm) in the ocular (Zeiss CPLWlOx/18) of an inverted microscope 
(Leitz Diavert). W ithin each well a t least six randomly chosen areas 
were counted, followed by the calculation of the mean and  the total 
num ber of nonaggregating  cells. Percent aggregation was determined 
according to the formula:
„  No. of free cells
Percent aggregation = 1 -------------------------  x 100%.
total No. of cells
The experim ents were carried out in triplicate. The SD within each 
experim ent was usually  less than 10%.
RESULTS
Immunoprécipitation, We previously described several 
antibodies reactive with LFA-1 (2). In a comparative im­
munoprécipitation study with 125I-labeled PHA-activated 
PBL, two newly generated antibodies L15 and LI6 showed 
the characteristic pattern of LFA-1 (Fig. 1 ). These mAb, like 
LI, L7, L10, L ll ,  and MHM 24, precipitated an a-chain
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Figure 1, Immunoprécipitation of LFA-1 from a 125I-labeled lysate of pe­
ripheral blood mononuclear cells, with various anti-LFA-1 mAb. Immuno­
precipitates were subjected to SDS-PAGE and autoradiography. (A) SPV-L1, 
(B) SPV-L7, (C) SPV-L10, (D) MHM 24, (£) SPV-L11, (F) NKI-L15. (G) NKI- 
L16, (H) MHM 23. (i) 60.3, and (J) CLB 54.
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with a Mr of 170 kDa and a /3-chain of 95 kDa, respectively. 
Anti-/3-chain mAb (CLB 54, MHM 23, 60.3) precipitate in 
addition to these two bands, the tt-chain of the p i 50*95 
molecule (Fig. 1). To prove that LI5 and L16 reacted with 
LFA-1 but not with an LFA-l-Iike Ag, preclear and peptide 
mapping experiments were carried out. Repeated preclear­
ing (4 times) of lysates of CTL with mAb 60.3 or L7, followed 
by immunoprécipitation with LI5 or LI6, resulted in a 
considerable reduction (>90%) of the immunoprecipitated 
material (results not shown). Similar observations were made 
in reciprocal experiments which indicates that mAb LI 5 
and LI 6 both recognize LFA-1. Further evidence is provided 
by a peptide map which was made of immunoprecipitates 
obtained with the mAb L ll, L15, L16, and MHM 24. The 
a- and/or /3-chains were excised from the gel, digested by 
V8 protease, and subsequently subjected to 8 to 15% SDS- 
PAGE. As shown in Figure 2, identical patterns were ob­
served, showing that all mAb recognize the LFA-1 Ag.
JY-JY interactions. Recently it has been reported that 
mAb directed against LFA-1 inhibit both spontaneous and 
TPA-induced homotypic cell-cell interactions of JY cells (12, 
13). The increased adhesion of cells after TPA stimulation 
could not be attributed to a higher expression of LFA-1 or 
to an increased motility. These results were confirmed as 
shown in Tables I and II. All mAb directed against LFA-1, 
except LI 6, strongly inhibited the aggregate formation of 
JY cells (Table I), whereas the increased adhesiveness caused 
by addition of TPA was not accompanied by an increased
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Figure 2. Treatment of the SDS-PAGE-purified a- and /3-chains of LFA-
1 with V8 protease. (A) LI 1 /3-ehain; (B) L16/3-chain; (C) MHM 24 a-chain; 
(D) L16 a-chain; (E) L15 a-chain; (F) LI 1 a-chain. Bars indicate relative Mr 
(kDa) as defined by prestained markers.
26-
expression of LFA-1 (Table II). Surprisingly, addition of mAb 
LI6 strongly stimulated the adhesive capacity of sponta­
neously aggregating JY cells, quite similar to TPA (Table I). 
In some experiments, stimulation of aggregation by mAb 
L16 could already be observed at a concentration of 50 ng/ 
ml (data not shown).
Both TPA induced JY cell clustering, and aggregation 
induced by mAb L I6, could be inhibited by all other anti- 
LFA-1 mAb available (Table I). To study the process of ag­
gregate formation in more detail and to compare the effects 
of TPA and mAb LI 6, kinetic experiments were performed. 
As shown in Figure 3, both mAb LI 6 and TPA induced a 
rapid cluster formation reaching a maximum (i.e., >90% 
of the cells in large compact clusters) after 3 h  of incubation 
at 37°C. Simultaneous addition of TPA and mAb LI 6 did 
not further accelerate the aggregation process in compar­
ison with the addition of either TPA or L16. The hyper­
aggregation induced by these compounds lasted for more 
than 72 h for both stimuli. Inhibition of spontaneous or 
stimulated aggregate formation induced by other anti-LFA- 
1 mAb decreased after 24 h (Fig. 3). Taken together these 
data suggest that TPA or L16 may induce aggregate for­
mation by a similar LFA-1-mediated mechanism.
We excluded the possibility that mAb L I6 accidently had 
been contaminated with TPA, since both hybridoma su- 
pernatants and HPLC-purified antibodies were effective in 
inducing aggregation. Furthermore, addition of TPA to 
neutrophils caused a rapid oxidative burst, whereas in con­
trast addition of mAb LI 6 was found to be ineffective (re­
sults not shown).
CTL-CTL interactions. In contrast to JY cells, unstim u­
lated cloned hum an CTL do not form spontaneous homo­
typic conjugates in vitro (Fig. 4). Nevertheless, the addition 
of small quantities of TPA (1 ng/ml) or mAb LI 6 (50 ng/ml) 
to a CD3+CD4~tCD16~ CTL clone (clone JS-136) induces 
rapid aggregation of the cells (Figs. 5 and 6, respectively). 
Similar results were obtained by using other CTL clones 
regardless of their phenotype. Similar to JY cells, the ag­
gregate formation of JS-136 cells induced by TPA was not 
accompanied by an increase in expression of LFA-1 on the 
cell surface of CTL (Table II). Nevertheless, aggregation in­
duced by mAb LI 6 or TPA seems to depend on the presence 
of LFA-1, since other anti-LFA-1 mAb were able to com­
pletely abrogate aggregation (Table I). Furthermore, anti- 
LFA-1 /3~chain mAb were found to be slightly less inhibitory 
than anti LFA-1 a-chain mAb, both for JY-JY and CTL-CTL 
interactions.
We also cai-ried out kinetic studies with JS-136 (Fig. 7). 
In spite of the 7- to 10-fold higher expression of LFA-1 on 
the CTL clones compared with JY cells (Table II), the onset 
of aggregation after addition of TPA or mAb L I6 occurred 
after 30 to 60 min. After this period, cells aggregated in a 
similar fashion as JY cells. In general, no differences in 
kinetics were observed between TPA treatment or stimu­
lation with L I6. Again, these data suggest that TPA- or 
L16-induced cell aggregation is mediated by a similar 
mechanism.
No involvement of FcR. Inasmuch as mAb L16 has a 
different iso type (IgG 2a) than most of the other anti-LFA- 
1 antibodies applied in this stujdy (Table I), induction of 
aggregate formation of JY cells or CTL might be due to an 
FcR-mediated process. However, strong evidence against 
this possibility comes from the following observations. (1) 
A control antibody, W6/32 (IgG2a) directed against HLA
TABLE I
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Ability o fm A b  to inhibit or stimulate formation o f spontaneous or induced homotypic cell aggregatesa
Ag mAb la o type
JY JS-136
Medium TPA L16 Medium TPA L16
3 4- 5 + 5 + 0 4 + 4 +
LFA-1 « MHM 24 IgGl 0 1 + 1 + 0 0 0
LFA-1 a LI IgGl 0 0 0 0 0 0
LFA-la L7 IgGl 0 0 1 + 0 0 0
LFA-la L10 IgGl 0 0 0 0 0 0
LFA-la L l l IgGl 0 0 0 0 0 0
LFA-la L15 IgGl 0 1 + 1 + 0 0 0
LFA-la L16 IgG2a 5 + 5 + 5 +■ 4 + 4 + 4 +
HLA-ABC- W6/32 IgG2a 3 + 5 + 5 + 0 4 -(■ 4 +
LFA- Iß 60.3 IgG2a 1 + 2 + 1 + 0 1 + 1 +
LFA* Iß MHM 23 IgGl 1 + 2-1- 2 + 0 1 + 1 +
LFA- Iß CLB 54 IgGl 1 + 1 1 + 0 1 + 1 +
Rupi-lb IgGl 3 + 5 + 5 + 0 4 + 4 4-
Klosb IgG2a 3 + 5-f 5 + 0 4 + 4 +
11 mAb (5 /xg/ml) were added to unstimulated and TPA (10 
(clone JS-136). After 4 h t the aggregate formation was scored 
b Antibodies nonreactive with the cells.
TABLE II
Expression of LFA-11 HLA class I, a n d  CD 16 antigens on J Y  cells and the 
CTL clone JS-136 as measured by an  indirect immunofluorescence
a ssa ya
Relative Fluorescence Intensily
mAb ------------------------------------------------------------------------------
JY JY (TPA) JS-136 JS-136 (TPA)
Klos 0.4 0.3 0 0
Rupi-1 0 0.1 0 0
L10 3.7 3.5 23.7 26.0
L16 3.2 3.4 15.5 15.1
60.3 3.7 3.6 22.5 25.0
W6/32 57.5 56.2 43.7 43.7
«-CD 16 ND ND 0 0
u Cells were cultured at 37°C and treated with or without TPA (10 ng/ml) 
for 1 h. Subsequently an immunofluorescence assay was performed as de­
scribed in Materials and  Methods. The results of a typical experiment are 
shown (n = 5).
time(min)
Figure 3 . Kinetics of aggregation of JY cells. Aggregation in the presence 
of TPA (■), 5 ng/ml; LIB (À), 0.1 Mg/ml or medium alone (•) .  The open 
symbols represent the addition of mAb CLB 54 (1 ¿ig/ml) to L16 stimulated 
(A) or unstimulated (O) cells,
class I Ag did not induce aggregate formation, despite the 
fact that these Ag are abundantly present on both CTL and 
JY cells (Table II); (2) the mAb 60.3 (IgG2a) which reacts 
with the /3-chain of LFA-1 strongly inhibits aggregate for­
mation (Table I); and (3) the CTL clone (JS-136) does not 
express FcR as judged by (a) nonreactivity with antibodies 
directed against CD 16 and (b) nonreactivity with a control 
mAb (KIos) of the same iso type (Table II).
Epitope determination. As described above, mAb di­
rected against LFA-1, with the exception of mAb L I6, In­
hibited homotypic aggregate formation. Therefore it was of 
interest to determine whether L16 reacted with a thus far 
unknown epitope of the LFA-1 molecule. The finding that 
L16 induces aggregate formation indicates that L I6 does 
not react with the binding site of LFA-1. To determine the
ng/ml)- or L16 (0.5 /¿g/ml)-stimulated JY cells or a CTL clone 
visually as described in Maieria/s and  Methods.
epitopes of the various LFA-1 antibodies, PHA-stimulated 
PBL were treated with tiypsin for various lengths of time, 
followed by immunofluorescence. As depicted in Figure 8A, 
mAb LI6 recognizes an epitope on the LFA-1 a-chain, which 
is relatively insensitive to trypsin treatment. After 2.5 min 
of treatment, no determinants were lost, and after 40 min 
almost 50% of the determinants were still conserved. In 
contrast, the mAb MHM 24, LI, L7, L10, LI 1, and LI5 were 
found to be reactive with an epitope which was already 
affected after 2.5 min of trypsin treatment. These mAb can 
be divided into two groups discernible after 40 min of ex­
posure to trypsin. mAb belonging to the first group (MHM 
24, LI, L7, and L10) lost all reactivity, whereas about 25% 
of the determinants recognized by the mAb of the second 
group (L ll and Ll5) were still present, Similar observa­
tions were made with anti-LFA-1 /3-chain mAb (Fig. 8B). 
All epitopes were found to be trypsin sensitive, but a clear 
distinction could be made between the epitopes recognized 
by mAb CLB 54 and the other two mAb (MHM 23 and 60.3). 
After 5 min of trypsin treatment, more than 50% of the 
epitope recognized by CLB 54 was lost, whereas the greater 
part of the epitope recognized by the mAb MHM 23 and 
60.3 was still present. It should be noted that, after 5 min 
of trypsin treatment, the /3-chain of LFA-1 becomes rela­
tively insensitive to further degradation for a period of ap­
proximately 15 min (Fig, 8B). These results indicate that 
the epitope recognized by mAb L16 is most likely located 
close to the transmembrane segment of the molecule suc­
cessively followed by the epitopes recognized by the mAb 
Ll l ,  L15, and the epitopes of L7, L10, L12, and MHM 24. 
Similarly, the mAb MHM 23 and 60.3 might bind closer to 
the transmembrane of the molecule than mAb CLB 54.
To determine whether the mAb directed against the var­
ious trypsin-defined epitopes could inhibit each other’s 
binding, cross-bio eking experiments were carried out. Within 
each of the trypsin-defined epitopes all mAb cross-blocked 
each other (Fig. 9). Moreover, binding of a mAb to one of 
the trypsin-defined epitopes does not inhibit binding of 
mAb to other trypsin-defined enitopes (Fig. 9). These re­
sults indicate that none of the trypsin-defined epitopes is 
lost due to conformational changes within the LFA-1 mol­
ecule after binding of a single mAb. Furthermore, these 
results show that both methods (trypsin treatment and 
cross-blocking studies) yield identical results. It is con­
cluded that mAb L I6 and CLB 54 define unique epitopes 
on the a- and /3-chain of LFA-1, respectively.
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Figure 4. Photomicrograph of aggregation of CTL (clone JS-136), after a 3-h incubation period with medium.
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Figure 5. Photomicrograph of CTL clone JS-136 aggregation after a 3-h incubation with TPA, 1 ng/ml.
DISCUSSION
Homotypic cellular interactions have been shown
mediated by an LPA-1-dependent mechanism since mAb 
directed against this Ag are able to inhibit cell clustering 
(10—12). From our findings it becomes clear that the
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Figure 6. Photomicrograph of aggregation of CTL clone JS-136 after a 3-h incubation with L16, 0.1 ¿¿g/ml.
time(min)
Figure 7. Kinetics of aggregation of CTL clone JS-136. Aggregation in 
the presence of TPA, 1 ng/ml (■) or L I6, 0.1 ¿u.g/ml (A). The open symbols 
represent unstimulated cells (O) and LI6 stimulated cells in the presence 
of mAb CLB 54, 10 /ig/ml (A).
expression of LFA-1 on the cell surface does not correlate 
with homotypic aggregate formation. First, weak LFA-1 
positive JY cells form spontaneous cell clusters, whereas 
strong LFA-1-positive CTL clones were shown not to ag­
gregate (Fig. 4). Second, induction of homotypic aggregate 
formation by means of TPA is not accompanied by an in­
crease in LFA-1 expression (Table II). Similar findings were 
reported by Rothlein and Springer (12) who in addition 
showed that LFA-1 is requird for cell aggregation since EBV- 
transformed LFA-1-negative B cell lines could not be in­
duced to form homotypic cell aggregates. However, these 
cells could bind to other LFA-1-positive EBV-transformed 
B cells. Furthermore, their results indicated that metabolic 
activity and cell motility are required for cell aggregation. 
The differences in kinetics of aggregation of CTL or JY cells
(Figs. 3 and 7) might be due to these phenomena since 
these cells may differ in their state of activation.
The mechanism whereby TPA induces aggregate forma­
tion has not yet been elucidated. Via triggering of the pro­
tein kinase C pathway, TPA may have effects on the cell 
membrane, cytoskeleton, or motility (12). Alternatively, TPA 
may act on LFA-1 itself. In this respect the characterization 
of mAb NKI-L16 may be helpful to further delineate the role 
of TPA in cell aggregation. mAb L16 is directed against the 
a:-chain of LFA-1 and stimulates cellular adhesion in a man­
ner similar to TPA (Figs. 3 and 7). Simultaneous addition 
of TPA and mAb L I6 did not further increase the speed of 
aggregation which suggests the involvement of a similar 
activation mechanism. From these data it can be hypoth­
esized that TPA may activate the LFA-1 molecule, by in­
ducing a conformation change possibly via protein kinase 
C and subsequent phosphorylation (26). Binding of mAb 
L I6 to LFA-1 may induce a similar conformational change 
leading to activation of the LFA-1 molecule. This hypothesis 
is supported by the finding that the epitope recognized by 
mAb L16 is most likely situated close to the transmembrane 
segment of the molecule which is nearest to the site of 
phorphorylation.
Taken together our results strongly indicate the exist­
ence of two forms of LFA-1, an active configuration by means 
of which cells aggregate in an LFA-1 dependent fashion, 
and an inactive configuration in which cells express LFA- 
1 but do not aggregate. A similar change in configuration 
has been postulated for CD2 (Til,  LFA-2) (6, 27—30). Like 
LFA-1, CD2 is involved in CTL- target cell adhesion (6, 31). 
In addition, CD2 appears to play an important role in T 
cell activation (32, 33). Upon cell activation, CD2 acquires 
a new epitope as recognized by a mAb termed anti-
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Figure 8. Epitope determination of the various anti-LFA-1 mAb by the 
use of trypsin. PHA-stimulated lymphocytes were treated with trypsin i'or 
various lengths of time after which an immunofluorescence assay was car­
ried out. The relative immunofluorescence of untreated samples represented 
the 100% value. (A) Trypsin sensitivity of the epitopes located on the en­
chain of LFA-1: LI (•), L7 (O), L10 (□), L l l  (A), L15 (A), L16 MHM 
24 (■). (B) Trypsin sensitivity of the epitopes located on the /3-chain of LFA- 
1: CLB 54 (■), 60.3 (A), MHM 23 (A).
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Figure 9 . Cross-blocking (■) of the various anti-LFA-1 mAb as detected 
by direct and indirect immunofluorescence (see Materials and  Methods). 
The open bars and dotted lines separate anti-LFA-1 a-chain and anti-LFA- 
1 /3-chain mAb, respectively.
T113 (32). The induction of the expression of this epitope 
is most likely caused by a conformational change in the 
molecule, since binding of another anti-CD2 mAb (anti- 
T112) to resting T cells for 30 min at 0°C induces the ap­
pearance of the T l l 3 epitope (32, 33). Interestingly, addi­
tion of anti-Tl 13 mAb together with certain other anti-CD2 
mAb stimulates rather than inhibits T cell functions (32— 
35), In this context it is noteworthy that the epitope rec­
ognized by mAb L16 is expressed only on activated cells, 
and is induced on resting PBL after mitogenic stimulation 
(G. D. Keizer, manuscript in preparation).
What is the natural signal that causes LFA-1 to switch 
from the resting to the activated state? The most simple 
explanation would be the presence of its counterstructure. 
Unfortunately, this model is too simple since CTL do not 
interact with each other spontaneously, whereas reason­
able evidence can be provided that the counterstructure is 
present on CTL. First, it is difficult to assume that binding 
of mAb LI 6 will induce aggregate formation of cells by in­
ducing the expression of a counterstructure of LFA-1. More­
over, the hypothetical counterstructure of LFA-1, the in­
tercellular adhesion molecule 1 (ICAM-1) (36) appears to be 
present on CTL (37). These results indicate that LFA-1 be­
comes activated via a different mechanism. One explana­
tion is that LFA-1 is not the adhesion-initiating molecule 
but may play a role in adhesion strengthening, which has 
been proposed by others (12, 38). In this regard, the ex­
istence of an LFA-1-independent adhesion pathway may be 
relevant as described both for CTL-target cell (31) and mon­
ocyte-endothelial cell interactions (39), In the latter case, 
Strassman et al. (40) elegantly demonstrated that weak 
LFA-1 independent adhesion preceded LFA-1 dependent cell­
cell interaction which resulted in strong adhesion. More­
over, it was shown that only the strong interaction, which 
could be accelerated by the addition of TPA, was inhibitable 
by anti-LFA-1 mAb in contrast to the initial weak cell-cell 
interactions (40, 41). Whether the LFA-1-independent 
pathway activates LFA-1 or whether LFA-1 is activated by 
a different mechanism remains to be determined.
To the best of otir knowledge, mAb LI6 is the first an­
tibody directed against human LFA-1 which stimulates cell- 
cell contact. Recently three antibodies (1-17, H155-78, and 
G-48) have been described, all reactive with LFA-1, which 
induce proliferation and/or aggregation of murine T and B 
cells (14—16). These effects cannot be easily explained by 
assuming that LFA-1 is just a general adhesion molecule 
without further function. It shoLild be noted, however, that 
proliferation occurred only after a second signal, i.e., ad­
dition of Ag (14), Con A supernatant on (15), or cross- 
linking 5-chains of, surface Ig molecules (16). From those 
studies and from the results reported here, it becomes clear 
that antibodies like L16 will be of great help to delineate 
the precise role of LFA-1.
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